Preview
Sign-in for full Details 
Sign-in free and Explore the Exciting World of BiomedExperts:
- Over 1.500.000 Profiles
- More than 1.800 Organizations worldwide
- State of the Art Network Visualizations
- Manage your own Profile
- Locate Experts in your Country/Region
- Locate Experts in your 1. and 2. Level Network
- Connect to Experts Worldwide
NetworkView
Norbert Bischofberger
This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers
together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles
free of charge to researchers worldwide.
Research Profile (preview)
Chemicals & Drugs
Disorders
Living Beings
Anatomy
Concepts & Ideas
Physiology
Sign-in to see full Profile
Network (preview)
17
Marthas, Marta
17
Van Rompay, Koen
8
Pedersen, Niels
8
Lifson, Jeffrey
7
Tsai, Che-Chung
6
Tarara, Ross
6
Canfield, Don
5
Chen, MS
5
Cherrington, Julie
5
Cundy, Kenneth
5
Dailey, PJ
5
Kim, Choung
5
Piatak, Michael
4
Singh, Raman
4
Lawson, Jonathan
Sign-in to see all Coauthors
Publications
Sign-in to see all Publications
Sign in free and see...
Visualized networks:
See your personal network in
sophisticated graphical views
GeoTargeted Searches:
Locate experts around the world
and connect with global collaborators
Research Profiles:
See the visualized research activity
of experts around the globe
Sign-in to see more
Geonetwork of Norbert Bischofberger (preview)
Cities where this author has publications
Cities where co-authors of this author have publications
Sign-in to see more
All Publications
-
2008: Van Rompay Koen K A; Durand-Gasselin Lucie; Brignolo Laurie L; Ray Adrian S; Abel Kristina; Cihlar Tomas; Spinner Abigail; Jerome Christopher; Moore Joseph; Kearney Brian P; Marthas Marta L; Reiser Hans; Bischofberger Norbert
Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects.
Antimicrobial agents and chemotherapy 2008;52(9):3144-60.
-
2007: Ambrose Zandrea; Palmer Sarah; Boltz Valerie F; Kearney Mary; Larsen Kay; Polacino Patricia; Flanary Leon; Oswald Kelli; Piatak Michael; Smedley Jeremy; Shao Wei; Bischofberger Norbert; Maldarelli Frank; Kimata Jason T; Mellors John W; Hu Shiu-Lok; Coffin John M; Lifson Jeffrey D; KewalRamani Vineet N
Suppression of viremia and evolution of human immunodeficiency virus type 1 drug resistance in a macaque model for antiretroviral therapy.
Journal of virology 2007;81(22):12145-55.
-
2007: von Gegerfelt Agneta S; Rosati Margherita; Alicea Candido; Valentin Antonio; Roth Patricia; Bear Jenifer; Franchini Genoveffa; Albert Paul S; Bischofberger Norbert; Boyer Jean D; Weiner David B; Markham Phillip; Israel Zimra R; Eldridge John H; Pavlakis George N; Felber Barbara K
Long-lasting decrease in viremia in macaques chronically infected with simian immunodeficiency virus SIVmac251 after therapeutic DNA immunization.
Journal of virology 2007;81(4):1972-9.
-
2007: Van Rompay Koen K A; Johnson Jeffrey A; Blackwood Emily J; Singh Raman P; Lipscomb Jonathan; Matthews Timothy B; Marthas Marta L; Pedersen Niels C; Bischofberger Norbert; Heneine Walid; North Thomas W
Sequential emergence and clinical implications of viral mutants with K70E and K65R mutation in reverse transcriptase during prolonged tenofovir monotherapy in rhesus macaques with chronic RT-SHIV infection.
Retrovirology 2007;4():25.
-
2006: Van Rompay Koen K A; Kearney Brian P; Sexton Jonathan J; Colón Roxana; Lawson Jonathan R; Blackwood Emily J; Lee William A; Bischofberger Norbert; Marthas Marta L
Evaluation of oral tenofovir disoproxil fumarate and topical tenofovir GS-7340 to protect infant macaques against repeated oral challenges with virulent simian immunodeficiency virus.
Journal of acquired immune deficiency syndromes (1999) 2006;43(1):6-14.
-
2006: Van Rompay Koen K A; Singh Raman P; Heneine Walid; Johnson Jeffrey A; Montefiori David C; Bischofberger Norbert; Marthas Marta L
Structured treatment interruptions with tenofovir monotherapy for simian immunodeficiency virus-infected newborn macaques.
Journal of virology 2006;80(13):6399-410.
-
2005: Williams Kenneth; Westmoreland Susan; Greco Jane; Ratai Eva; Lentz Margaret; Kim Woong-Ki; Fuller Robert A; Kim John P; Autissier Patrick; Sehgal Prahbat K; Schinazi Raymond F; Bischofberger Norbert; Piatak Michael; Lifson Jeffrey D; Masliah Eliezer; González R Gilberto
Magnetic resonance spectroscopy reveals that activated monocytes contribute to neuronal injury in SIV neuroAIDS.
The Journal of clinical investigation 2005;115(9):2534-45.
-
2005: Van Rompay Koen K A; Hamilton Marta; Kearney Brian; Bischofberger Norbert
Pharmacokinetics of tenofovir in breast milk of lactating rhesus macaques.
Antimicrobial agents and chemotherapy 2005;49(5):2093-4.
-
2004: Van Rompay Koen K A; Marthas Marta L; Bischofberger Norbert
Tenofovir primes rhesus macaque cells in vitro for enhanced interleukin-12 secretion.
Antiviral research 2004;63(2):133-8.
-
2004: Van Rompay Koen K A; Singh Raman P; Brignolo Laurie L; Lawson Jonathan R; Schmidt Kimberli A; Pahar Bapi; Canfield Don R; Tarara Ross P; Sodora Donald L; Bischofberger Norbert; Marthas Marta L
The clinical benefits of tenofovir for simian immunodeficiency virus-infected macaques are larger than predicted by its effects on standard viral and immunologic parameters.
Journal of acquired immune deficiency syndromes (1999) 2004;36(4):900-14.
-
2004: Van Rompay Koen K A; Singh Raman P; Pahar Bapi; Sodora Donald L; Wingfield Casey; Lawson Jonathan R; Marthas Marta L; Bischofberger Norbert
CD8+-cell-mediated suppression of virulent simian immunodeficiency virus during tenofovir treatment.
Journal of virology 2004;78(10):5324-37.
-
2004: Van Rompay Koen K A; Brignolo Laurie L; Meyer Dennis J; Jerome Christopher; Tarara Ross; Spinner Abigail; Hamilton Marta; Hirst Linda L; Bennett David R; Canfield Don R; Dearman Trish G; Von Morgenland Wilhelm; Allen Phil C; Valverde Celia; Castillo Alesha B; Martin R Bruce; Samii Valerie F; Bendele Ray; Desjardins John; Marthas Marta L; Pedersen Niels C; Bischofberger Norbert
Biological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy)propyl]adenine (tenofovir) to newborn and infant rhesus macaques.
Antimicrobial agents and chemotherapy 2004;48(5):1469-87.
-
2003: Lifson J D; Piatak M; Cline A N; Rossio J L; Purcell J; Pandrea I; Bischofberger N; Blanchard J; Veazey R S
Transient early post-inoculation anti-retroviral treatment facilitates controlled infection with sparing of CD4+ T cells in gut-associated lymphoid tissues in SIVmac239-infected rhesus macaques, but not resistance to rechallenge.
Journal of medical primatology 2003;32(4-5):201-10.
-
2002: Van Rompay Koen K A; Schmidt Kimberli A; Lawson Jonathan R; Singh Raman; Bischofberger Norbert; Marthas Marta L
Topical administration of low-dose tenofovir disoproxil fumarate to protect infant macaques against multiple oral exposures of low doses of simian immunodeficiency virus.
The Journal of infectious diseases 2002;186(10):1508-13.
-
2002: Tarantal Alice F; Castillo Alesha; Ekert Jason E; Bischofberger Norbert; Martin R Bruce
Fetal and maternal outcome after administration of tenofovir to gravid rhesus monkeys (Macaca mulatta).
Journal of acquired immune deficiency syndromes (1999) 2002;29(3):207-20.
-
2001: Lifson J D; Rossio J L; Piatak M; Parks T; Li L; Kiser R; Coalter V; Fisher B; Flynn B M; Czajak S; Hirsch V M; Reimann K A; Schmitz J E; Ghrayeb J; Bischofberger N; Nowak M A; Desrosiers R C; Wodarz D
Role of CD8(+) lymphocytes in control of simian immunodeficiency virus infection and resistance to rechallenge after transient early antiretroviral treatment.
Journal of virology 2001;75(21):10187-99.
-
2001: Van Rompay K K; McChesney M B; Aguirre N L; Schmidt K A; Bischofberger N; Marthas M L
Two low doses of tenofovir protect newborn macaques against oral simian immunodeficiency virus infection.
The Journal of infectious diseases 2001;184(4):429-38.
-
2000: Hel Z; Venzon D; Poudyal M; Tsai W P; Giuliani L; Woodward R; Chougnet C; Shearer G; Altman J D; Watkins D; Bischofberger N; Abimiku A; Markham P; Tartaglia J; Franchini G
Viremia control following antiretroviral treatment and therapeutic immunization during primary SIV251 infection of macaques.
Nature medicine 2000;6(10):1140-6.
-
2000: Tsai C C; Emau P; Sun J C; Beck T W; Tran C A; Follis K E; Bischofberger N; Morton W R
Post-exposure chemoprophylaxis (PECP) against SIV infection of macaques as a model for protection from HIV infection.
Journal of medical primatology 2000;29(3-4):248-58.
-
2000: Fox H S; Weed M R; Huitron-Resendiz S; Baig J; Horn T F; Dailey P J; Bischofberger N; Henriksen S J
Antiviral treatment normalizes neurophysiological but not movement abnormalities in simian immunodeficiency virus-infected monkeys.
The Journal of clinical investigation 2000;106(1):37-45.
-
2000: Lifson J D; Rossio J L; Arnaout R; Li L; Parks T L; Schneider D K; Kiser R F; Coalter V J; Walsh G; Imming R J; Fisher B; Flynn B M; Bischofberger N; Piatak M; Hirsch V M; Nowak M A; Wodarz D
Containment of simian immunodeficiency virus infection: cellular immune responses and protection from rechallenge following transient postinoculation antiretroviral treatment.
Journal of virology 2000;74(6):2584-93.
-
2000: Van Rompay K K; Miller M D; Marthas M L; Margot N A; Dailey P J; Canfield D R; Tarara R P; Cherrington J M; Aguirre N L; Bischofberger N; Pedersen N C
Prophylactic and therapeutic benefits of short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) administration to newborn macaques following oral inoculation with simian immunodeficiency virus with reduced susceptibility to PMPA.
Journal of virology 2000;74(4):1767-74.
-
2000: Laver W G; Bischofberger N; Webster R G
The origin and control of pandemic influenza.
Perspectives in biology and medicine 2000;43(2):173-92.
-
1999: Van Rompay K K; Cherrington J M; Marthas M L; Lamy P D; Dailey P J; Canfield D R; Tarara R P; Bischofberger N; Pedersen N C
9-[2-(Phosphonomethoxy)propyl]adenine (PMPA) therapy prolongs survival of infant macaques inoculated with simian immunodeficiency virus with reduced susceptibility to PMPA.
Antimicrobial agents and chemotherapy 1999;43(4):802-12.
-
1999: Tarantal A F; Marthas M L; Shaw J P; Cundy K; Bischofberger N
Administration of 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) to gravid and infant rhesus macaques (Macaca mulatta): safety and efficacy studies.
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 1999;20(4):323-33.
-
1999: van Rompay K K; Dailey P J; Tarara R P; Canfield D R; Aguirre N L; Cherrington J M; Lamy P D; Bischofberger N; Pedersen N C; Marthas M L
Early short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine treatment favorably alters the subsequent disease course in simian immunodeficiency virus-infected newborn Rhesus macaques.
Journal of virology 1999;73(4):2947-55.
-
1999: Laver W G; Bischofberger N; Webster R G
Disarming flu viruses.
Scientific American 1999;280(1):78-87.
-
1998: Naesens L; Bischofberger N; Augustijns P; Annaert P; Van den Mooter G; Arimilli M N; Kim C U; De Clercq E
Antiretroviral efficacy and pharmacokinetics of oral bis(isopropyloxycarbonyloxymethyl)-9-(2-phosphonylmethoxypropyl)adenine in mice.
Antimicrobial agents and chemotherapy 1998;42(7):1568-73.
-
1998: Van Rompay K K; Berardi C J; Aguirre N L; Bischofberger N; Lietman P S; Pedersen N C; Marthas M L
Two doses of PMPA protect newborn macaques against oral simian immunodeficiency virus infection.
AIDS (London, England) 1998;12(9):F79-83.
-
1998: Van Rompay K K; Marthas M L; Lifson J D; Berardi C J; Vasquez G M; Agatep E; Dehqanzada Z A; Cundy K C; Bischofberger N; Pedersen N C
Administration of 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) for prevention of perinatal simian immunodeficiency virus infection in rhesus macaques.
AIDS research and human retroviruses 1998;14(9):761-73.
-
1998: Tsai C C; Emau P; Follis K E; Beck T W; Benveniste R E; Bischofberger N; Lifson J D; Morton W R
Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment.
Journal of virology 1998;72(5):4265-73.
-
1998: Li W; Escarpe P A; Eisenberg E J; Cundy K C; Sweet C; Jakeman K J; Merson J; Lew W; Williams M; Zhang L; Kim C U; Bischofberger N; Chen M S; Mendel D B
Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071.
Antimicrobial agents and chemotherapy 1998;42(3):647-53.
-
1998: Mendel D B; Tai C Y; Escarpe P A; Li W; Sidwell R W; Huffman J H; Sweet C; Jakeman K J; Merson J; Lacy S A; Lew W; Williams M A; Zhang L; Chen M S; Bischofberger N; Kim C U
Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection.
Antimicrobial agents and chemotherapy 1998;42(3):640-6.
-
1997: Nowak M A; Lloyd A L; Vasquez G M; Wiltrout T A; Wahl L M; Bischofberger N; Williams J; Kinter A; Fauci A S; Hirsch V M; Lifson J D
Viral dynamics of primary viremia and antiretroviral therapy in simian immunodeficiency virus infection.
Journal of virology 1997;71(10):7518-25.
-
1997: Tsai C C; Follis K E; Beck T W; Sabo A; Bischofberger N; Dailey P J
Effects of (R)-9-(2-phosphonylmethoxypropyl)adenine monotherapy on chronic SIV infection in macaques.
AIDS research and human retroviruses 1997;13(8):707-12.
-
1997: Kim C U; Lew W; Williams M A; Liu H; Zhang L; Swaminathan S; Bischofberger N; Chen M S; Mendel D B; Tai C Y; Laver W G; Stevens R C
Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity.
Journal of the American Chemical Society 1997;119(4):681-90.
-
1996: Von Lubitz D K; Lin R C; Paul I A; Beenhakker M; Boyd M; Bischofberger N; Jacobson K A
Postischemic administration of adenosine amine congener (ADAC): analysis of recovery in gerbils.
European journal of pharmacology 1996;316(2-3):171-9.
-
1996: Van Rompay K K; Cherrington J M; Marthas M L; Berardi C J; Mulato A S; Spinner A; Tarara R P; Canfield D R; Telm S; Bischofberger N; Pedersen N C
9-[2-(Phosphonomethoxy)propyl]adenine therapy of established simian immunodeficiency virus infection in infant rhesus macaques.
Antimicrobial agents and chemotherapy 1996;40(11):2586-91.
-
1996: Kim C U; McGee L R; Krawczyk S H; Harwood E; Harada Y; Swaminathan S; Bischofberger N; Chen M S; Cherrington J M; Xiong S F; Griffin L; Cundy K C; Lee A; Yu B; Gulnik S; Erickson J W
New series of potent, orally bioavailable, non-peptidic cyclic sulfones as HIV-1 protease inhibitors.
Journal of medicinal chemistry 1996;39(18):3431-4.
-
1996: Von Lubitz D K; Beenhakker M; Lin R C; Carter M F; Paul I A; Bischofberger N; Jacobson K A
Reduction of postischemic brain damage and memory deficits following treatment with the selective adenosine A1 receptor agonist.
European journal of pharmacology 1996;302(1-3):43-8.
-
1996: Naesens L; Balzarini J; Bischofberger N; De Clercq E
Antiretroviral activity and pharmacokinetics in mice of oral bis(pivaloyloxymethyl)-9-(2-phosphonylmethoxyethyl)adenine, the bis(pivaloyloxymethyl) ester prodrug of 9-(2-phosphonylmethoxyethyl)adenine.
Antimicrobial agents and chemotherapy 1996;40(1):22-8.
-
1995: Tsai C C; Follis K E; Sabo A; Beck T W; Grant R F; Bischofberger N; Benveniste R E; Black R
Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine.
Science (New York, N.Y.) 1995;270(5239):1197-9.
-
1995: Tsai C C; Follis K E; Sabo A; Grant R; Bischofberger N
Efficacy of 9-(2-phosphonylmethoxyethyl)adenine treatment against chronic simian immunodeficiency virus infection in macaques.
The Journal of infectious diseases 1995;171(5):1338-43.
-
1994: Bischofberger N; Hitchcock M J; Chen M S; Barkhimer D B; Cundy K C; Kent K M; Lacy S A; Lee W A; Li Z H; Mendel D B
1-[((S)-2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl] cytosine, an intracellular prodrug for (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine with improved therapeutic index in vivo.
Antimicrobial agents and chemotherapy 1994;38(10):2387-91.
-
1994: Tsai C C; Follis K E; Sabo A; Grant R F; Bartz C; Nolte R E; Benveniste R E; Bischofberger N
Preexposure prophylaxis with 9-(2-phosphonylmethoxyethyl)adenine against simian immunodeficiency virus infection in macaques.
The Journal of infectious diseases 1994;169(2):260-6.
-
1994: Tsai C C; Follis K E; Grant R; Sabo A; Nolte R; Bartz C; Bischofberger N; Benveniste R
Comparison of the efficacy of AZT and PMEA treatment against acute SIVmne infection in macaques.
Journal of medical primatology 1994;23(2-3):175-83.
-
1993: Wang K Y; Krawczyk S H; Bischofberger N; Swaminathan S; Bolton P H
The tertiary structure of a DNA aptamer which binds to and inhibits thrombin determines activity.
Biochemistry 1993;32(42):11285-92.
-
1990: Shea R G; Ng P; Bischofberger N
Thermal denaturation profiles and gel mobility shift analysis of oligodeoxynucleotide triplexes.
Nucleic acids research 1990;18(16):4859-66.
-
1990: Shea R G; Marsters J C; Bischofberger N
Synthesis, hybridization properties and antiviral activity of lipid-oligodeoxynucleotide conjugates.
Nucleic acids research 1990;18(13):3777-83.
Sign-in to see more
